TY  - JOUR
AU  - Mijušković, Mirjana
AU  - Stanojević, Ivan
AU  - Milović, Novak
AU  - Cerović, Snežana
AU  - Petrović, Dejan
AU  - Maksić, Đoko
AU  - Kovacević, Božidar
AU  - Anđelić, Tamara
AU  - Aleksić, Predrag
AU  - Terzić, Brankica
AU  - Đukić, Mirjana
AU  - Vojvodić, Danilo
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3231
AB  - The objective of this prospective follow-up trial was to ascertain whether the urinary kidney injury molecule-1 (uKIM-1) associates with tumor tissue (tKIM-1) expression and with the pathological characteristics of clear renal cell carcinoma (cRCC) in radically nephrectomized (RN) and/or in partially nephrectomized (PN) patients with cRCC, pre- and postoperatively. This clinical study included 40 patients subjected to RN/PN (cRCC group) and 30 healthy volunteers (control group). Urinary KIM-1 was determined by ELISA TIM-1/KIM-1 kit and normalized by urinary creatinine. Immunohistochemical staining (monoclonal anti-human anti-TIM-1/KIM-1/HAVCR antibody) was used for semiquantitative analysis of the tKIM-1 expression and expressed as a score (% KIM-1 positively stained tubules). Both markers were interpreted in terms of the tumor characteristics comprising tumor size, Fuhrman grade, pathological (pT) stage, tumor/nodes/metastasis (TNM) stage, lymphovascular invasion and type of surgery RN/PN. Preoperative uKIM-1 was significantly higher in the cRCC group compared to controls, such as uKIM-1 was statistically higher in RN than in PN patients. Postoperatively, uKIM-1 decreased to control values. Expression of tKIM-1 was documented in all nephrectomized patients. Significant associations were achieved between uKIM-1 and tKIM-1 and with considered tumor characteristics, especially with tumor size and grade. Based on the accomplished associations, we found uKIM-1 as a highly sensitive marker for cRCC diagnosis. The clinical trial registration number: 1110-2012.
PB  - Springer, Dordrecht
T2  - International Urology and Nephrology
T1  - Tissue and urinary KIM-1 relate to tumor characteristics in patients with clear renal cell carcinoma
VL  - 50
IS  - 1
SP  - 63
EP  - 70
DO  - 10.1007/s11255-017-1724-6
ER  - 

@article{
author = "Mijušković, Mirjana and Stanojević, Ivan and Milović, Novak and Cerović, Snežana and Petrović, Dejan and Maksić, Đoko and Kovacević, Božidar and Anđelić, Tamara and Aleksić, Predrag and Terzić, Brankica and Đukić, Mirjana and Vojvodić, Danilo",
year = "2018",
abstract = "The objective of this prospective follow-up trial was to ascertain whether the urinary kidney injury molecule-1 (uKIM-1) associates with tumor tissue (tKIM-1) expression and with the pathological characteristics of clear renal cell carcinoma (cRCC) in radically nephrectomized (RN) and/or in partially nephrectomized (PN) patients with cRCC, pre- and postoperatively. This clinical study included 40 patients subjected to RN/PN (cRCC group) and 30 healthy volunteers (control group). Urinary KIM-1 was determined by ELISA TIM-1/KIM-1 kit and normalized by urinary creatinine. Immunohistochemical staining (monoclonal anti-human anti-TIM-1/KIM-1/HAVCR antibody) was used for semiquantitative analysis of the tKIM-1 expression and expressed as a score (% KIM-1 positively stained tubules). Both markers were interpreted in terms of the tumor characteristics comprising tumor size, Fuhrman grade, pathological (pT) stage, tumor/nodes/metastasis (TNM) stage, lymphovascular invasion and type of surgery RN/PN. Preoperative uKIM-1 was significantly higher in the cRCC group compared to controls, such as uKIM-1 was statistically higher in RN than in PN patients. Postoperatively, uKIM-1 decreased to control values. Expression of tKIM-1 was documented in all nephrectomized patients. Significant associations were achieved between uKIM-1 and tKIM-1 and with considered tumor characteristics, especially with tumor size and grade. Based on the accomplished associations, we found uKIM-1 as a highly sensitive marker for cRCC diagnosis. The clinical trial registration number: 1110-2012.",
publisher = "Springer, Dordrecht",
journal = "International Urology and Nephrology",
title = "Tissue and urinary KIM-1 relate to tumor characteristics in patients with clear renal cell carcinoma",
volume = "50",
number = "1",
pages = "63-70",
doi = "10.1007/s11255-017-1724-6"
}

Mijušković, M., Stanojević, I., Milović, N., Cerović, S., Petrović, D., Maksić, Đ., Kovacević, B., Anđelić, T., Aleksić, P., Terzić, B., Đukić, M.,& Vojvodić, D.. (2018). Tissue and urinary KIM-1 relate to tumor characteristics in patients with clear renal cell carcinoma. in International Urology and Nephrology
Springer, Dordrecht., 50(1), 63-70.
https://doi.org/10.1007/s11255-017-1724-6

Mijušković M, Stanojević I, Milović N, Cerović S, Petrović D, Maksić Đ, Kovacević B, Anđelić T, Aleksić P, Terzić B, Đukić M, Vojvodić D. Tissue and urinary KIM-1 relate to tumor characteristics in patients with clear renal cell carcinoma. in International Urology and Nephrology. 2018;50(1):63-70.
doi:10.1007/s11255-017-1724-6 .

Mijušković, Mirjana, Stanojević, Ivan, Milović, Novak, Cerović, Snežana, Petrović, Dejan, Maksić, Đoko, Kovacević, Božidar, Anđelić, Tamara, Aleksić, Predrag, Terzić, Brankica, Đukić, Mirjana, Vojvodić, Danilo, "Tissue and urinary KIM-1 relate to tumor characteristics in patients with clear renal cell carcinoma" in International Urology and Nephrology, 50, no. 1 (2018):63-70,
https://doi.org/10.1007/s11255-017-1724-6 . .

TY  - JOUR
AU  - Stanojević, Ivan
AU  - Miller, Karolina
AU  - Kandolf-Sekulović, Lidija
AU  - Mijušković, Željko
AU  - Zolotarevska, Lidija
AU  - Jović, Milena
AU  - Gacević, Milomir
AU  - Đukić, Mirjana
AU  - Arsenijević, Nebojša
AU  - Vojvodić, Danilo
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2565
AB  - Seventy-eight melanoma patients and 10 healthy individuals were examined. Follow-up examinations of all melanoma patients were performed regularly every three months. Myeloid-derived suppressor cells (MDSC) were defined as lineage negative (CD3(-), CD19(-), CD56(-)), HLA-DR-/low, CD11b(+) and CD33(+). Classification of granulocytic (GrMDSC) and monocytic (MoMDSC) subsets was based on the CD15 and CD14 expression, respectively. Unlike the MoMDSC, that were present in 60% of healthy controls and 15% of melanoma patients, the GrMDSC were present in all examined participants, and the melanoma patients were found to have statistically higher frequencies compared with healthy controls. Accordingly, we kept focused on GrMDSC frequencies in relation to the melanoma stages and course of the disease. The GrMDSC values are highest in stage IV melanoma patients, with statistical significance compared with stages IA, IB, IIA and IIB. Patients with progression had statistically higher GrMDSC counts comparing with those with stable disease (P = 0.0079). Patients who had progression-free interval (PFI)  lt  12 months showed significantly higher GrMDSC values compared with those with PFI > 12 months (P = 0.0333). GrMDSC showed significant negative correlation with PFI intervals (P = 0.0095). The GrMDSC subset was predominant in all our patients. We confirmed that GrMDSC do accumulate early in the peripheral blood of melanoma patients and their frequencies correlate narrowly with the clinical stage and the spread of the disease. The increase in GrMDSC frequencies correlates well with a progressive disease and could be considered a potential predictive biomarker of high-risk melanoma cases that are more likely to have a shorter PFI.
PB  - Oxford Univ Press, Oxford
T2  - International Immunology
T1  - A subpopulation that may correspond to granulocytic myeloid-derived suppressor cells reflects the clinical stage and progression of cutaneous melanoma
VL  - 28
IS  - 2
SP  - 87
EP  - 97
DO  - 10.1093/intimm/dxv053
ER  - 

@article{
author = "Stanojević, Ivan and Miller, Karolina and Kandolf-Sekulović, Lidija and Mijušković, Željko and Zolotarevska, Lidija and Jović, Milena and Gacević, Milomir and Đukić, Mirjana and Arsenijević, Nebojša and Vojvodić, Danilo",
year = "2016",
abstract = "Seventy-eight melanoma patients and 10 healthy individuals were examined. Follow-up examinations of all melanoma patients were performed regularly every three months. Myeloid-derived suppressor cells (MDSC) were defined as lineage negative (CD3(-), CD19(-), CD56(-)), HLA-DR-/low, CD11b(+) and CD33(+). Classification of granulocytic (GrMDSC) and monocytic (MoMDSC) subsets was based on the CD15 and CD14 expression, respectively. Unlike the MoMDSC, that were present in 60% of healthy controls and 15% of melanoma patients, the GrMDSC were present in all examined participants, and the melanoma patients were found to have statistically higher frequencies compared with healthy controls. Accordingly, we kept focused on GrMDSC frequencies in relation to the melanoma stages and course of the disease. The GrMDSC values are highest in stage IV melanoma patients, with statistical significance compared with stages IA, IB, IIA and IIB. Patients with progression had statistically higher GrMDSC counts comparing with those with stable disease (P = 0.0079). Patients who had progression-free interval (PFI)  lt  12 months showed significantly higher GrMDSC values compared with those with PFI > 12 months (P = 0.0333). GrMDSC showed significant negative correlation with PFI intervals (P = 0.0095). The GrMDSC subset was predominant in all our patients. We confirmed that GrMDSC do accumulate early in the peripheral blood of melanoma patients and their frequencies correlate narrowly with the clinical stage and the spread of the disease. The increase in GrMDSC frequencies correlates well with a progressive disease and could be considered a potential predictive biomarker of high-risk melanoma cases that are more likely to have a shorter PFI.",
publisher = "Oxford Univ Press, Oxford",
journal = "International Immunology",
title = "A subpopulation that may correspond to granulocytic myeloid-derived suppressor cells reflects the clinical stage and progression of cutaneous melanoma",
volume = "28",
number = "2",
pages = "87-97",
doi = "10.1093/intimm/dxv053"
}

Stanojević, I., Miller, K., Kandolf-Sekulović, L., Mijušković, Ž., Zolotarevska, L., Jović, M., Gacević, M., Đukić, M., Arsenijević, N.,& Vojvodić, D.. (2016). A subpopulation that may correspond to granulocytic myeloid-derived suppressor cells reflects the clinical stage and progression of cutaneous melanoma. in International Immunology
Oxford Univ Press, Oxford., 28(2), 87-97.
https://doi.org/10.1093/intimm/dxv053

Stanojević I, Miller K, Kandolf-Sekulović L, Mijušković Ž, Zolotarevska L, Jović M, Gacević M, Đukić M, Arsenijević N, Vojvodić D. A subpopulation that may correspond to granulocytic myeloid-derived suppressor cells reflects the clinical stage and progression of cutaneous melanoma. in International Immunology. 2016;28(2):87-97.
doi:10.1093/intimm/dxv053 .

Stanojević, Ivan, Miller, Karolina, Kandolf-Sekulović, Lidija, Mijušković, Željko, Zolotarevska, Lidija, Jović, Milena, Gacević, Milomir, Đukić, Mirjana, Arsenijević, Nebojša, Vojvodić, Danilo, "A subpopulation that may correspond to granulocytic myeloid-derived suppressor cells reflects the clinical stage and progression of cutaneous melanoma" in International Immunology, 28, no. 2 (2016):87-97,
https://doi.org/10.1093/intimm/dxv053 . .